Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pandemic Influenza alphavaccine (H5)
- Development stage
- Unknown
- Lead developer
- AlphaVax
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pandemic Influenza alphavaccine (H5) is an investigational RNA-based vaccine developed by AlphaVax for the prevention of H5N1 pandemic influenza. It utilizes the AlphaVax Replicon Vector (VRP) technology, which is derived from an attenuated strain of the Venezuelan Equine Encephalitis (VEE) virus. In this system, the structural genes of the alphavirus are replaced with the gene encoding the H5 influenza hemagglutinin (HA) antigen. The resulting replication-defective viral replicon particles (VRPs) infect target cells and express high levels of the H5 antigen, stimulating both humoral and cellular immune responses without producing new infectious virus particles. This platform is designed to provide rapid and robust protection against pandemic strains by mimicking a natural viral infection at the cellular level to enhance immunogenicity.
- Other names
- AlphaVax H5 vaccineH5N1 VRP vaccineH-5N1 VRP vaccineH 5N1 VRP vaccinealphavirus replicon particle vaccine (H5)VRP-H5VRP-H-5VRP-H 5
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Pandemic Influenza alphavaccine (H5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pandemic Influenza alphavaccine (H5).